Teva’s subcutaneous asthma drug fails in PhIII
admin 23rd January 2018 Uncategorised 0Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
More: Teva’s subcutaneous asthma drug fails in PhIII
Source: News